Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) CFO Benjamin Hohl Sells 6,018 Shares

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) CFO Benjamin Hohl sold 6,018 shares of Bitwise MARA Option Income Strategy ETF stock in a transaction on Friday, July 17th. The shares were sold at an average price of $52.64, for a total value of $316,787.52. Following the sale, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at approximately $2,424,282.56. This trade represents a 11.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Bitwise MARA Option Income Strategy ETF stock. The stock was sold at an average price of $43.80, for a total value of $263,588.40.

Bitwise MARA Option Income Strategy ETF Trading Down 0.2%

IMRA opened at $14.49 on Wednesday. Bitwise MARA Option Income Strategy ETF has a 12-month low of $11.99 and a 12-month high of $43.70. The business’s fifty day simple moving average is $16.52 and its 200-day simple moving average is $15.48. The company has a market capitalization of $1.88 million, a price-to-earnings ratio of 289.80 and a beta of 2.74.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.